SOST and osteogenesis imperfecta: In the realm of anti-sclerostin agents, Glorieux et al. expounded on the application of BPS804 in adults with moderate OI, demonstrating that BPS804 increased BMD, reduced resorption, and stimulated bone formation (Glorieux et al. 2017).